Cetera Advisors LLC Purchases New Holdings in AstraZeneca plc (NYSE:AZN)

Cetera Advisors LLC bought a new stake in AstraZeneca plc (NYSE:AZN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,925 shares of the company’s stock, valued at approximately $339,000.

Other hedge funds have also recently made changes to their positions in the company. Premier Asset Management LLC grew its position in AstraZeneca by 8.0% in the 4th quarter. Premier Asset Management LLC now owns 32,700 shares of the company’s stock valued at $1,242,000 after buying an additional 2,425 shares in the last quarter. Covington Capital Management boosted its position in shares of AstraZeneca by 1,100.0% during the 4th quarter. Covington Capital Management now owns 2,400 shares of the company’s stock valued at $91,000 after purchasing an additional 2,200 shares in the last quarter. Wexford Capital LP bought a new position in shares of AstraZeneca during the 4th quarter valued at about $7,504,000. IHT Wealth Management LLC boosted its position in shares of AstraZeneca by 9.9% during the 4th quarter. IHT Wealth Management LLC now owns 13,754 shares of the company’s stock valued at $522,000 after purchasing an additional 1,235 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of AstraZeneca during the 4th quarter valued at about $8,220,000. Institutional investors and hedge funds own 18.31% of the company’s stock.

AZN stock traded up $0.03 during midday trading on Wednesday, hitting $38.72. 3,087,708 shares of the company traded hands, compared to its average volume of 5,483,647. AstraZeneca plc has a twelve month low of $34.38 and a twelve month high of $43.29. The company has a quick ratio of 0.78, a current ratio of 0.96 and a debt-to-equity ratio of 1.24. The company has a market cap of $98.24 billion, a PE ratio of 11.19, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, February 14th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.73 by $0.85. AstraZeneca had a return on equity of 32.47% and a net margin of 9.76%. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.33 billion. During the same quarter last year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, equities analysts expect that AstraZeneca plc will post 1.78 EPS for the current fiscal year.

The business also recently declared a semiannual dividend, which was paid on Wednesday, March 27th. Shareholders of record on Friday, March 1st were issued a dividend of $0.95 per share. This represents a yield of 4.64%. The ex-dividend date of this dividend was Thursday, February 28th. This is an increase from AstraZeneca’s previous semiannual dividend of $0.45. AstraZeneca’s dividend payout ratio (DPR) is 53.76%.

A number of analysts have commented on the stock. Zacks Investment Research raised shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Tuesday, April 16th. UBS Group lowered shares of AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price objective for the company. in a research note on Tuesday, April 2nd. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Cowen raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $42.00 to $48.00 in a research report on Monday, April 1st. Finally, Main First Bank reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 19th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $45.29.

TRADEMARK VIOLATION WARNING: “Cetera Advisors LLC Purchases New Holdings in AstraZeneca plc (NYSE:AZN)” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/24/cetera-advisors-llc-purchases-new-holdings-in-astrazeneca-plc-azn.html.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: What do I need to know about analyst ratings?

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.